Rasonque Posts $197.6M in Q3 Net Revenue

Revolution Medicines' pancreatic cancer drug generated the figure after FDA approval in August.

Updated on Nov. 16, 2026 in Cancer

Rasonque Posts $197.6M in Q3 Net Revenue

Live Poll

Do you trust new cancer drugs will be priced fairly for patients like you?

Revolution Medicines reported that Rasonque, its pancreatic cancer drug, generated $197.6 million in net product revenue during third-quarter earnings. The US Food and Drug Administration approved the drug in August, and it has been recommended for approval in Europe.

Why it matters

Phase III RASolute 302 results showed median survival of 12.4 months on Rasonque versus 6.7 months with chemotherapy, a gap that bears directly on patients with limited treatment options. Early commercial uptake offers an initial signal of how the drug may be adopted as it reaches additional markets.

Phase III RASolute 302 showed median survival of 12.4 months on Rasonque versus 6.7 months on chemotherapy in pancreatic cancer patients. Pricing and reimbursement outside the US have not been decided and will be set country by country.

The players

Revolution Medicines

A clinical-stage biopharmaceutical company focused on developing targeted therapies against RAS-driven cancers.

Mark Goldsmith

Chief executive of Revolution Medicines who oversees the company's commercial and clinical strategy.

The details

Rasonque inhibits RAS, a protein involved in cell growth and survival. More than 2,000 patients were enrolled in the FDA expanded access programme, and many transitioned to the commercial drug after approval.

Timeline

  1. August 2026: FDA approves Rasonque for pancreatic cancer.

  2. 2026 ASCO Annual Meeting: Full RASolute 302 data first presented.

  3. Mid-October 2026: William Blair analysts issue research note praising the launch.

  4. 16 November 2026: CEO Mark Goldsmith discusses launch complexity at the Jefferies Global Healthcare Conference in London.

Treatment Landscape

The commercial launch follows the Phase III RASolute 302 trial, which established the survival benefit that now shapes Rasonque's prescribing. Patients previously treated but not advanced to third or fourth line are expected to form the core population for the drug going forward.

Rasonque's availability will depend on pricing and reimbursement decisions made country by country, so access may vary for patients outside the US. The US list price is $39,800 for a month's supply, a figure that affects treatment decisions for patients and families.

The takeaway

Rasonque's survival data in pancreatic cancer give patients previously treated with chemotherapy a documented option, though its reach beyond the US depends on how each country prices and reimburses it.

Further reading

Explore more on Cancer treatments and their commercial rollout.

Live Poll

Do you trust new cancer drugs will be priced fairly for patients like you?